The Journal of Practical Medicine >
Potential value of liver macrophages and their plasticity in the treatment of ACLF
Received date: 2024-02-28
Online published: 2024-07-15
Acute-on-chronic liver failure （ACLF） is a group of clinical syndromes related to severe acute liver function damage and multiple organ failure caused by various acute inducing factors on the basis of chronic liver disease. Due to its serious condition， rapid progression and high mortality， it has attracted more and more attention. Recent studies have shown that the pathogenesis of ACLF mainly includes direct injury and immune injury. As the main immune cells in the liver， the immunoregulatory role of liver macrophages in ACLF has been increasingly recognized. Liver macrophages have excellent phenotype conversion function and plasticity characteristics under the influence of epigenetic reprogramming or local microenvironment. This adaptive expression ability can use key mediators to promote the early conversion of anti-inflammatory phenotype to alleviate liver injury. A large number of studies have shown that liver macrophages have a certain potential in reversing the process of ACLF. Therefore， from the perspective of the plasticity characteristics of liver macrophages， this paper expounds the role of liver macrophages in ACLF and the research on the intervention of ACLF disease process， and summarizes its potential significance in the treatment of ACLF.
Guirong CHEN , Minggang WANG , Huaming LIN , Xinxin CHEN , Juan LUO , Fengqin YE , Xiufeng. WANG . Potential value of liver macrophages and their plasticity in the treatment of ACLF[J]. The Journal of Practical Medicine, 2024 , 40(14) : 2035 -2040 . DOI: 10.3969/j.issn.1006-5725.2024.14.023
| 1 | HERNAEZ R， LI H， MOREAU R， et al. Diagnosis and epidemiology of acute-on-chronic liver failure［J］. Liver Int， 2023. doi： 10.1111/liv.15670 . |
| 2 | PAPACHRISTOFOROU E， RAMACHANDRAN P. Macrophages as key regulators of liver health and disease［J］. Int Rev Cell Mol Biol， 2022，368：143-212. doi:10.1016/bs.ircmb.2022.04.006 |
| 3 | MASS E， NIMMERJAHN F， KIERDORF K，et al. Tissue-specific macrophages： how they develop and choreograph tissue biology［J］. Nat Rev Immunol， 2023，23（9）：563-579. doi:10.1038/s41577-023-00848-y |
| 4 | WANG C， MA C， GONG L， et al. Macrophage Polarization and Its Role in Liver Disease［J］. Front Immunol， 2021，12：803037. doi:10.3389/fimmu.2021.803037 |
| 5 | YUNNA C， MENGRU H， LEI W，et al. Macrophage M1/M2 polarization［J］. Eur J Pharmacol， 2020，877：173090. doi:10.1016/j.ejphar.2020.173090 |
| 6 | VIOLA A， MUNARI F， SáNCHEZ-RODRíGUEZ R，et al. The Metabolic Signature of Macrophage Responses［J］. Front Immunol， 2019，10：1462. doi:10.3389/fimmu.2019.01462 |
| 7 | MANTOVANI A， SICA A， SOZZANI S，et al. The chemokine system in diverse forms of macrophage activation and polarization［J］. Trends Immunol， 2004，25（12）：677-686. doi:10.1016/j.it.2004.09.015 |
| 8 | SHAPOURI-MOGHADDAM A， MOHAMMADIAN S， VAZINI Het al. Macrophage plasticity， polarization， and function in health and disease［J］. J Cell Physiol， 2018，233（9）：6425-6440. doi:10.1002/jcp.26429 |
| 9 | HEYMANN F， PEUSQUENS J， LUDWIG-PORTUGALL I，et al. Liver inflammation abrogates immunological tolerance induced by Kupffer cells［J］. Hepatology， 2015，62（1）：279-291. doi:10.1002/hep.27793 |
| 10 | JU C， TACKE F. Hepatic macrophages in homeostasis and liver diseases： from pathogenesis to novel therapeutic strategies［J］. Cell Mol Immunol， 2016，13（3）：316-327. doi:10.1038/cmi.2015.104 |
| 11 | ZENG Z， SUREWAARD B G， WONG C H，et al. CRIg Functions as a Macrophage Pattern Recognition Receptor to Directly Bind and Capture Blood-Borne Gram-Positive Bacteria［J］. Cell Host Microbe， 2016，20（1）：99-106. doi:10.1016/j.chom.2016.06.002 |
| 12 | LUO Z， JI Y， GAO H，et al. CRIg+ Macrophages Prevent Gut Microbial DNA-Containing Extracellular Vesicle-Induced Tissue Inflammation and Insulin Resistance［J］. Gastroenterology， 2021，160（3）：863-874. doi:10.1053/j.gastro.2020.10.042 |
| 13 | DEPPERMANN C， KRATOFIL R M， PEISELER M，et al. Macrophage galactose lectin is critical for Kupffer cells to clear aged platelets［J］. J Exp Med， 2020，217（4）：e20190723. doi:10.1084/jem.20190723 |
| 14 | WANG Y， VAN DER TUIN S， TJEERDEMA N，et al. Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells［J］. Hepatology， 2015，62（6）：1710-1722. doi:10.1002/hep.27985 |
| 15 | DIEHL K L， VORAC J， HOFMANN K，et al. Kupffer Cells Sense Free Fatty Acids and Regulate Hepatic Lipid Metabolism in High-Fat Diet and Inflammation［J］. Cells， 2020，9（10）：2258. doi:10.3390/cells9102258 |
| 16 | LI L， CUI L， LIN P，et al. Kupffer-cell-derived IL-6 is repurposed for hepatocyte dedifferentiation via activating progenitor genes from injury-specific enhancers［J］. Cell Stem Cell， 2023，30（3）：283-299.e9. doi:10.1016/j.stem.2023.01.009 |
| 17 | SELZNER N， SELZNER M， ODERMATT B， et al. ICAM-1 triggers liver regeneration through leukocyte recruitment and Kupffer cell-dependent release of TNF-alpha/IL-6 in mice［J］. Gastroenterology， 2003，124（3）：692-700. doi:10.1053/gast.2003.50098 |
| 18 | ELCHANINOV A V， FATKHUDINOV T K， VISHNYAKOVA P A，et al. Phenotypical and Functional Polymorphism of Liver Resident Macrophages［J］. Cells， 2019，8（9）：1032. doi:10.3390/cells8091032 |
| 19 | WEN Y， LAMBRECHT J， JU C，et al. Hepatic macrophages in liver homeostasis and diseases-diversity， plasticity and therapeutic opportunities［J］. Cell Mol Immunol， 2021，18（1）：45-56. doi:10.1038/s41423-020-00558-8 |
| 20 | KOU K， SUN X， TIAN G，et al. The Mechanisms of Systemic Inflammatory and Immunosuppressive Acute-on-Chronic Liver Failure and Application Prospect of Single-Cell Sequencing［J］. J Immunol Res， 2022，2022：5091275. doi:10.1155/2022/5091275 |
| 21 | BERNARDI M， MOREAU R， ANGELI P，et al. Mechanisms of decompensation and organ failure in cirrhosis： From peripheral arterial vasodilation to systemic inflammation hypothesis［J］. J Hepatol， 2015，63（5）：1272-1284. doi:10.1016/j.jhep.2015.07.004 |
| 22 | SOLé C， SOLà E， MORALES-RUIZ M，et al. Characterization of Inflammatory Response in Acute-on-Chronic Liver Failure and Relationship with Prognosis［J］. Sci Rep， 2016，6：32341. doi:10.1038/srep32341 |
| 23 | PENG J， LI J， HUANG J，et al. p300/CBP inhibitor A-485 alleviates acute liver injury by regulating macrophage activation and polarization［J］. Theranostics， 2019，9（26）：8344-8361. doi:10.7150/thno.30707 |
| 24 | BERNSMEIER C， POP O T， SINGANAYAGAM A，et al. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK［J］. Gastroenterology， 2015，148（3）：603-615.e14. doi:10.1053/j.gastro.2014.11.045 |
| 25 | YANG Q， LIU Y， SHI Y，et al. The role of intracellular high-mobility group box 1 in the early activation of Kupffer cells and the development of Con A-induced acute liver failure［J］. Immunobiology， 2013，218（10）：1284-1292. doi:10.1016/j.imbio.2013.04.011 |
| 26 | WANG J， ZHANG X， HAN J，et al. MicroRNA-124 expression in Kupffer cells modulates liver injury by targeting IL-6/STAT3 signaling［J］. Antiviral Res， 2023，211：105510. doi:10.1016/j.antiviral.2022.105510 |
| 27 | BAI L， LU W， TANG S，et al. Galectin-3 critically mediates the hepatoprotection conferred by M2-like macrophages in ACLF by inhibiting pyroptosis but not necroptosis signalling［J］. Cell Death Dis， 2022，13（9）：775. doi:10.1038/s41419-022-05181-1 |
| 28 | PENG B， LI H， LIU K，et al. Intrahepatic macrophage reprogramming associated with lipid metabolism in hepatitis B virus-related acute-on-chronic liver failure［J］. J Transl Med， 2023，21（1）：419. doi:10.1186/s12967-023-04294-1 |
| 29 | 柳梅，亓敏，丁雷，等. 血浆髓样细胞触发受体2联合终末期肝病模型评分对乙型肝炎病毒相关慢加急性肝衰竭患者近期预后的预测价值［J］. 实用医学杂志， 2022，38（4）：473-478. doi:10.3969/j.issn.1006-5725.2022.04.015 |
| 30 | TONG J， WANG H， XU X，et al. Granulocyte Colony-Stimulating Factor Accelerates the Recovery of Hepatitis B Virus-Related Acute-on-Chronic Liver Failure by Promoting M2-Like Transition of Monocytes［J］. Front Immunol， 2022，13：885829. doi:10.3389/fimmu.2022.885829 |
| 31 | YAO Y， ZHANG L， CHENG F，et al. PPARγ-dependent hepatic macrophage switching acts as a central hub for hUCMSC-mediated alleviation of decompensated liver cirrhosis in rats［J］. Stem Cell Res Ther， 2023，14（1）：184. doi:10.1186/s13287-023-03416-2 |
| 32 | LI Z H， CHEN J F， ZHANG J，et al. Mesenchymal Stem Cells Promote Polarization of M2 Macrophages in Mice with Acute-On-Chronic Liver Failure via Mertk/JAK1/STAT6 Signaling［J］. Stem Cells， 2023，41（12）：1171-1184. doi:10.1093/stmcls/sxad069 |
| 33 | HU X H， CHEN L， WU H，et al. Cell therapy in end-stage liver disease： replace and remodel［J］. Stem Cell Res Ther， 2023，14（1）：141. doi:10.1186/s13287-023-03370-z |
| 34 | CARDINALE V， LANTHIER N， BAPTISTA P M，et al. Cell transplantation-based regenerative medicine in liver diseases［J］. Stem Cell Reports， 2023，18（8）：1555-1572. doi:10.1016/j.stemcr.2023.06.005 |
| 35 | STARKEY LEWIS P J， MORONI F， FORBES S J. Macrophages as a Cell-Based Therapy for Liver Disease［J］. Semin Liver Dis，2019，39（4）：442-451. doi:10.1055/s-0039-1688502 |
| 36 | STARKEY LEWIS P， CAMPANA L， ALEKSIEVA N，et al. Alternatively activated macrophages promote resolution of necrosis following acute liver injury［J］. J Hepatol， 2020，73（2）：349-360. doi:10.1016/j.jhep.2020.02.031 |
| 37 | MA P F， GAO C C， YI J，et al. Cytotherapy with M1-polarized macrophages ameliorates liver fibrosis by modulating immune microenvironment in mice［J］. J Hepatol， 2017，67（4）：770-779. doi:10.1016/j.jhep.2017.05.022 |
| 38 | MORONI F， DWYER B J， GRAHAM C，et al. Safety profile of autologous macrophage therapy for liver cirrhosis［J］. Nat Med，2019，25（10）：1560-1565. doi:10.1038/s41591-019-0599-8 |
/
| 〈 |
|
〉 |